Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved tucatinib (Tukysa) combined with trastuzumab and pertuzumab as maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. The decision was backed by the phase 3 HER2CLIMB-05 trial, which showed a 35.9% reduction in the risk of disease progression or death versus placebo. Median PFS jumped from 16.3 months to 24.9 months with the tucatinib regimen.
The FDA has officially approved tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and pertuzumab (Perjeta) as a maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. This marks a meaningful new option for patients whose disease hasn't progressed after standard induction chemotherapy.
The approval was driven by results from the randomized, double-blind, phase 3 HER2CLIMB-05 trial, where the tucatinib-based regimen significantly outperformed placebo plus trastuzumab/pertuzumab. Experts note that while this is an important escalation option post-induction, not every patient will need it — some do well long-term on trastuzumab/pertuzumab alone, underscoring the need for better biomarkers to guide treatment decisions.
By the Numbers:
Why it matters: This approval gives oncologists a new, evidence-backed maintenance strategy that meaningfully extends progression-free survival in a challenging cancer population, while also highlighting the ongoing need for biomarkers to personalize treatment intensity.
